Penumbra Company Profile (NYSE:PEN)

Analyst Ratings

Consensus Ratings for Penumbra (NYSE:PEN) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $53.00 (12.27% downside)

Analysts' Ratings History for Penumbra (NYSE:PEN)
Show:
DateFirmActionRatingPrice TargetActions
7/20/2016Canaccord GenuitySet Price TargetBuy$67.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/14/2016Wells Fargo & Co.Reiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/13/2015Bank of America Corp.Initiated CoverageBuy -> Buy$46.00 -> $46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/13/2015JPMorgan Chase & Co.Initiated CoverageOverweight$46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Penumbra (NYSE:PEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
5/9/2016Q116($0.07)$0.02$53.10 million$57.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/8/2016Q415($0.10)$0.05$46.76 million$54.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.15)$0.03$43.00 million$50.42 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Penumbra (NYSE:PEN)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Penumbra (NYSE:PEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Penumbra (NYSE:PEN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/23/2016Robert D EvansEVPSell5,000$50.52$252,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2016Don W KassingDirectorSell3,000$48.63$145,890.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2016Robert D EvansEVPBuy1,538$25.50$39,219.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016James Robert PrayInsiderSell32,500$48.51$1,576,575.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Penumbra (NYSE:PEN)
DateHeadline
07/25/16 07:08 AMPenumbra Launches Newest Stroke Thrombectomy Technology ACE™68 Reperfusion Catheter at SNIS 2016 - [at noodls] - http://www.businesswire.com/news/home/20160725005231/en/ The ACE™68 Reperfusion Catheter, part of the fully integrated Penumbra System®, leverages the latest advancements in tracking technology to deliver ...
07/20/16 08:39 AMShares Positive Over the Past Month: Penumbra, Inc. (NYSE:PEN) - TGP
07/20/16 08:39 AMBalasa Dinverno Foltz adds Penumbra Inc (PEN) to its portfolio - TheFounders Daily
07/19/16 03:45 PM4:45 pm Penumbra 3D Revascularization Device trial results to be presented at late breaking abstract presentations session at Society of NeuroInterventional Surgery Meeting July 25-28 -
07/19/16 03:01 PMPenumbra Announces Key Events at Society of NeuroInterventional Surgery 2016 Meeting - [Business Wire] - Penumbra, Inc. , a global interventional therapies company, today announced its schedule of key events at the Society of NeuroInterventional Surgery 13th Annual Meeting to be held July 25-28 in Boston, Massachusetts.
07/19/16 05:55 AMPenumbra Inc (NYSE:PEN) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/19/16 05:55 AMStock in Positive Territory for the Quarter: Penumbra, Inc. (NYSE:PEN) - Engelwood Daily
07/19/16 05:55 AMSolid Performer in Focus: Penumbra, Inc. (NYSE:PEN) - Engelwood Daily
07/19/16 05:55 AMEarnings Focus and Crowd Sourced Sentiment Review for Penumbra Inc (NYSE:PEN) - TGP
07/16/16 09:02 AMNeurovascular Devices Market Revenue and Value Chain 2016-2026
07/15/16 04:48 PMPenumbra, Inc. to Present at the Canaccord Genuity 36th Annual Growth Conference - PR Newswire (press release)
07/15/16 03:28 PMPenumbra, Inc. to Present at the Canaccord Genuity 36th Annual Growth Conference - [at noodls] - ALAMEDA, Calif., July 15, 2016 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, today announced that its management team is scheduled to present at the Canaccord Genuity ...
07/15/16 03:28 PMPenumbra, Inc. Schedules Second Quarter 2016 Earnings Release and Conference Call for August 9, 2016 at 4:30 PM Eastern Time - [at noodls] - ALAMEDA, Calif., July 15, 2016 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter ended June 30, 2016, after ...
07/15/16 10:51 AMAre Analysts Bullish Penumbra Inc (NYSE:PEN) After Last Week? - Press Telegraph
07/14/16 09:23 AMPenumbra, Inc. (NYSE:PEN) Updated Price Targets - FTSE News
07/14/16 09:23 AMAnalyst Target and Average Rating Watch: Penumbra Inc (NYSE:PEN) - Press Telegraph
07/14/16 09:23 AMShares Losing Ground for the Month; Investor Alert on Penumbra, Inc. (NYSE:PEN) - Engelwood Daily
07/14/16 09:23 AMPenumbra Inc (NYSE:PEN) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/14/16 09:23 AMPenumbra Inc versus The Spectranetics Corporation Head to Head Compare - CML News
07/10/16 05:04 PMStock on the Rise for the Quarter: Penumbra, Inc. (NYSE:PEN) - Engelwood Daily
07/10/16 05:04 PMNext Weeks Broker Price Targets For Penumbra, Inc. (NYSE:PEN) - Fiscal Standard
07/09/16 08:56 AMAnalyst Review Alert: Penumbra, Inc. (PEN) - Post Registrar
07/09/16 08:56 AMPenumbra, Inc. (NYSE:PEN) Current Analyst Ratings - Fiscal Standard
07/08/16 08:43 AMPenumbra Inc (NYSE:PEN) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/08/16 08:43 AMHow Many Penumbra Inc (NYSE:PEN)'s Analysts Are Bearish? - Press Telegraph
07/06/16 10:24 AMShares Providing Results This Month for Investors: Penumbra, Inc. (NYSE:PEN) - Telanagana Press
07/06/16 10:24 AMCan Penumbra Inc (NYSE:PEN) Improve on the Earnings Front? - Engelwood Daily
07/05/16 05:31 PMGlobal Market study on Intracranial Stents By 2021, PMR New Report
07/03/16 09:58 AMNeurovascular Devices/Interventional Neurology Marketis Poised to Reach $2,370.4 Million by 2020, with a Highest Growing CAGR of 8.4%
06/30/16 06:03 PMNew Broker Ratings For Penumbra, Inc. (NYSE:PEN) - FTSE News
06/30/16 06:03 PMHow Analysts Feel About Penumbra Inc (NYSE:PEN)? - Engelwood Daily
06/30/16 08:38 AMPenumbra Inc (NYSE:PEN) Company Rating and Target Watch - Telanagana Press
06/28/16 10:37 AMPenumbra, Inc. (NYSE:PEN) Broker Price Targets For The Coming Week - Fiscal Standard
06/28/16 10:37 AMTop Stock Pick for Quarter: Penumbra, Inc. (NYSE:PEN) - Engelwood Daily
06/26/16 10:15 AMStock Tracing Lower on the Week Penumbra, Inc. (NYSE:PEN) - Engelwood Daily
06/26/16 10:15 AMNoticeable Analyst's ideas: MediciNova, Inc. (NASDAQ:MNOV) , Penumbra, Inc. (NYSE:PEN) - Street Updates
06/23/16 08:28 AMPenumbra, Inc. (NYSE:PEN) take heat post earnings - iStreetWire
06/20/16 07:22 AMPenumbra, Inc. (NYSE:PEN) Analyst Price Targets For The Coming Week - Fiscal Standard
06/16/16 06:01 PMNeurointerventional Devices Market Opportunity Assessment by 2025
06/16/16 09:57 AMIntracranial Stents Market : Size, Share, Development, Growth and Demand Forecast to 2015 – 2021
06/13/16 07:34 AMWhy Penumbra (PEN) Could Be Positioned for a Surge? -
06/09/16 08:45 AMHealthcare Highs: Medtronic plc (NYSE:MDT), Nevro Corp. (NYSE:NVRO), Penumbra, Inc. (NYSE:PEN), DENTSPLY ... - KC Register
06/09/16 05:09 AMPENUMBRA INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/07/16 07:05 AMPenumbra (PEN) in Focus: Stock Adds 5.5% in Session -
06/03/16 08:30 AMRedmile Group Sticking With Healthcare Picks After Rough Q1 -
06/02/16 06:10 PMStock Review and Earnings Check on Penumbra Inc (NYSE:PEN) - HNN - Stock Review and Earnings Check on Penumbra Inc (NYSE:PEN)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Penumbra Inc (NYSE:PEN) to ...
06/02/16 06:10 PMAnalysts Set $54.33 Price Target for Penumbra Inc (NYSE:PEN) - Let Me Know About This - Analysts Set $54.33 Price Target for Penumbra Inc (NYSE:PEN)Let Me Know About ThisPenumbra logo Penumbra Inc (NYSE:PEN) has earned a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong ...
06/02/16 08:47 AMBuy, Sell Or Hold Rating For Penumbra, Inc. (NYSE:PEN)? - Share Trading News - Buy, Sell Or Hold Rating For Penumbra, Inc. (NYSE:PEN)?Share Trading News12/16/2015 – Penumbra, Inc. had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 60 price target on the stock. 10/13/2015 – Bank of America Merrill Lynch began new coverage on Penumbra, Inc. giving the company a “buy” ...
05/31/16 09:35 AMStock Paining Investors: Penumbra, Inc. (NYSE:PEN) - HNN - Stock Paining Investors: Penumbra, Inc. (NYSE:PEN)HNNPenumbra, Inc. (NYSE:PEN)'s P/E is 1301.71. P/E ratio indicates that a stock's price might be too high or too low when compared to its earnings. There are some investors who might think that a company with a high P/E is overpriced, though sometimes ...and more »
05/26/16 07:06 PMETF’s with exposure to Penumbra, Inc. : May 27, 2016 -

Social

About Penumbra

Penumbra logoPenumbra, Inc. (Penumbra) is an interventional therapies company. The Company designs, develops, manufactures and markets medical devices. The Company has a portfolio of products that addresses medical conditions and significant clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. The Company focuses on developing, manufacturing and marketing products for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. Its neuro products include Neurovascular Access, Ischemic Stroke, Neurovascular Embolization and Neurosurgical Tools. The Company's peripheral vascular products include Peripheral Embolization and Peripheral Thrombectomy.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: PEN
  • CUSIP:
Key Metrics:
  • Previous Close: $60.41
  • 50 Day Moving Average: $59.50
  • 200 Day Moving Average: $51.40
  • P/E Ratio: 981.45
  • P/E Growth: -9.36
  • Market Cap: $1.87B
  • Current Year EPS Consensus Estimate: $-0.19 EPS
  • Next Year EPS Consensus Estimate: $-0.05 EPS
Additional Links:
Penumbra (NYSE:PEN) Chart for Monday, July, 25, 2016